Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE vs BENZONATATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Temporary relief of cough due to minor throat and bronchial irritation (FDA-approved),Off-label: symptomatic treatment of upper respiratory tract infections with cough and congestion
Symptomatic relief of cough
For adults and children ≥12 years: 10 m L (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 m L (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.
100 mg to 200 mg orally three times daily as needed for cough.
Guaifenesin: 1-2 hours; Dextromethorphan: 3-6 hours (extensive metabolizers), 18-24 hours (poor metabolizers due to CYP2D6 polymorphism).
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Guaifenesin is metabolized by oxidation and demethylation; dextromethorphan is extensively metabolized by CYP2D6 to dextrorphan (active metabolite) and other metabolites.
Metabolized by plasma esterases (including pseudocholinesterase) to tetracaine and other metabolites.
Guaifenesin: ~60% renal (metabolites), ~35% fecal; Dextromethorphan: ~70% renal (parent and metabolites, 45% as unchanged dextrorphan), ~20% biliary/fecal.
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Guaifenesin: negligible (<10%); Dextromethorphan: ~60-70% (mainly albumin and alpha-1-acid glycoprotein).
Approximately 75–85% bound primarily to albumin.
Guaifenesin: 1.2 L/kg (distributes into tissues); Dextromethorphan: 5-7 L/kg (large Vd due to high tissue binding).
Approximately 3.5 L/kg, indicating extensive tissue distribution.
Oral: Guaifenesin ~95%; Dextromethorphan ~11% (extensive first-pass metabolism, variable due to CYP2D6).
Oral: Estimated 20–30% due to extensive first-pass metabolism.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of dextromethorphan metabolite.
No specific dosage adjustment is recommended for renal impairment per manufacturer; however, caution and monitoring are advised.
For dextromethorphan: Child-Pugh class C: consider reducing dose by 50% or avoid use; Child-Pugh A/B: no specific adjustment but monitor for CNS effects.
No specific dosage adjustment is recommended for hepatic impairment per manufacturer; however, caution is advised.
Children 6-11 years: 5 m L (100 mg guaifenesin, 10 mg dextromethorphan) every 4 hours, max 30 m L/day. Children 2-5 years: 2.5 m L (50 mg guaifenesin, 5 mg dextromethorphan) every 4 hours, max 15 m L/day. Not for children <2 years.
Safety and efficacy have not been established in children under 10 years of age. For children ≥10 years, adult dosing can be considered.
Use the lowest effective dose; consider starting with 5 m L (100 mg guaifenesin, 10 mg dextromethorphan) every 4-6 hours due to increased risk of sedation and anticholinergic effects.
Elderly patients may be more sensitive to CNS effects; start at lower end of dosing range (100 mg three times daily) and monitor carefully.
None.
None
Avoid use in patients with chronic cough (e.g., smoking, asthma, emphysema) or cough with excessive phlegm.,Concomitant use with MAOIs or within 2 weeks of MAOI use is contraindicated.,Dextromethorphan abuse potential; use caution with CYP2D6 inhibitors.
Severe allergic reactions (e.g., bronchospasm, laryngospasm, cardiovascular collapse) have been reported, especially with chewing or sucking capsules.,Capsules must be swallowed whole to avoid oral mucosal anesthesia and choking hazard.,Use with caution in patients with hypersensitivity to ester-type local anesthetics.,Safety and efficacy in children <10 years not established.
Hypersensitivity to guaifenesin or dextromethorphan,Concurrent use or recent use (within 2 weeks) of monoamine oxidase inhibitors (MAOIs),Severe hypertension, coronary artery disease, or narrow-angle glaucoma (due to sympathomimetic effects if combined with decongestants; note: this combination alone does not contain decongestants, but caution applies)
Hypersensitivity to benzonatate or related compounds (e.g., tetracaine, procaine)
No significant food interactions; avoid alcohol as it may increase sedation and dizziness.
No significant food interactions. The manufacturer does not list any specific dietary restrictions, but alcohol may enhance central nervous system side effects such as drowsiness.
Guaifenesin: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Dextromethorphan: No increased risk of major malformations in first trimester; animal studies show no teratogenicity. Avoid excessive doses in third trimester due to potential neonatal withdrawal or respiratory depression. Overall, both agents are considered low risk but use only if clearly needed.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near term. Second and third trimesters: Avoid use due to potential for neonatal apnea and withdrawal; benzonatate is a local anesthetic with CNS depressant effects.
Guaifenesin: Excreted in breast milk in small amounts; unlikely to cause adverse effects in infants. Dextromethorphan: Excreted in breast milk; limited data suggest low infant exposure (M/P ratio not established). Both are considered compatible with breastfeeding; use lowest effective dose and monitor infant for sedation or respiratory depression.
No data on excretion in human milk; M/P ratio unknown. Benzonatate and its metabolites may be present in breast milk. Caution advised due to potential for infant CNS depression and apnea. Consider benefit of breastfeeding vs risk of drug exposure.
No pharmacokinetic data to support dose adjustments during pregnancy; use lowest effective dose for shortest duration. Guaifenesin: increased renal clearance in pregnancy may theoretically reduce efficacy, but no dose adjustment recommended. Dextromethorphan: metabolism by CYP2D6 may be affected by pregnancy; avoid exceeding standard doses.
No pharmacokinetic studies in pregnancy. Dose adjustments not established. Use lowest effective dose if necessary. Avoid in third trimester due to neonatal risk. Increased plasma volume may reduce drug levels, but lack of data prevents formal dose adjustment recommendations.
Monitor for sedation and dizziness, especially in elderly; avoid use with MAOIs due to serotonin syndrome risk; dextromethorphan has abuse potential at high doses; use caution in patients with chronic cough due to smoking, asthma, or COPD; guaifenesin may cause renal calculi with prolonged high doses.
Benzonatate is a peripherally acting antitussive that anesthetizes stretch receptors in the respiratory tract. Onset of action is within 15-20 minutes and lasts 3-8 hours. Capsules must be swallowed whole; chewing or sucking can cause oropharyngeal anesthesia and choking hazard. Use with caution in patients with a history of drug allergy to tetracaine or other ester-type anesthetics. It is contraindicated in children under 10 years due to increased risk of adverse effects. Overdose can cause seizures, cardiac arrest, and death; treatment is supportive with no specific antidote.
Do not exceed recommended doses; high doses can cause serious side effects including hallucinations and addiction.,Avoid driving or operating machinery if you feel dizzy or drowsy.,Do not use with other cough and cold medications to avoid overdose.,Increase fluid intake to help loosen mucus.,Stop use and consult a doctor if cough persists more than 7 days or comes with fever, rash, or headache.,Inform your doctor about all medications you take, especially MAOIs or SSRIs.,Keep out of reach of children; accidental overdose may be fatal in children.
Swallow the capsule whole; do not chew, suck, or crush it, as this can cause numbness in your mouth or throat and increase risk of choking.,Take the medication exactly as prescribed; do not take more than directed.,This medication may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Contact your doctor if your cough persists for more than 5 days, or if it is accompanied by fever, rash, or persistent headache.,Keep out of reach of children; accidental ingestion can be fatal in children under 10.,Store at room temperature away from moisture and heat.
"The combination of dextromethorphan, a centrally acting antitussive with NMDA receptor antagonist and sigma-1 receptor agonist properties, and aceprometazine, a phenothiazine neuroleptic with strong antihistaminergic and moderate anticholinergic and antidopaminergic effects, can result in additive central nervous system depression. This interaction may lead to excessive sedation, respiratory depression, impaired psychomotor function, and an increased risk of falls or cognitive impairment, particularly in elderly or debilitated patients. Concurrent use may also lower the seizure threshold, especially in patients with predisposing factors."
"Dextromethorphan, a serotonergic agent metabolized by CYP2D6, when combined with cariprazine, a dopamine D3/D2 receptor partial agonist, may increase the risk of serotonin syndrome due to additive serotonergic effects. Cariprazine can inhibit CYP2D6, reducing dextromethorphan clearance and elevating its plasma concentration, leading to enhanced serotonin activity. Clinically, patients may present with altered mental status, autonomic instability, and neuromuscular abnormalities."
"Dextromethorphan inhibits CYP2B6 and CYP2C9, which are involved in valproic acid metabolism. This results in decreased valproic acid clearance, potentially elevating valproic acid serum concentrations and increasing the risk of dose-dependent adverse effects such as hepatotoxicity, thrombocytopenia, and sedation. Concurrent use requires dose adjustment and close monitoring for signs of valproate toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE vs BENZONATATE, answered by our medical review team.
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE is a Expectorant/Antitussive Combination that works by Guaifenesin is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity. Dextromethorphan is a centrally acting cough suppressant that binds to NMDA receptors and sigma-1 receptors, elevating the cough threshold.. BENZONATATE is a Antitussive that works by Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE and BENZONATATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE is: For adults and children ≥12 years: 10 m L (200 mg guaifenesin, 20 mg dextromethorphan) orally every 4 hours, not to exceed 60 m L (1200 mg guaifenesin, 120 mg dextromethorphan) per 24 hours.. The standard adult dose of BENZONATATE is: 100 mg to 200 mg orally three times daily as needed for cough.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE and BENZONATATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE is classified as Category C. Guaifenesin: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Dextromethorphan: No increased risk of major malformations in first trimester; . BENZONATATE is classified as Category A/B. FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies not available. Theoretical risk of fetal bradycardia and respiratory depression if used near te. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.